Status:
TERMINATED
[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
Lead Sponsor:
AHS Cancer Control Alberta
Conditions:
Renal Cell Carcinoma
Neuroendocrine Tumours
Eligibility:
All Genders
16+ years
Phase:
PHASE1
PHASE2
Brief Summary
Positron Emission Tomography (PET) is a Nuclear Medicine procedure that uses positron emitting radiolabeled tracer molecules to visualize biological activity. The presence of hypoxia (low oxygen) is a...
Detailed Description
The proposed clinical trial will be a Phase I/II imaging, open label, single site study. In Phase I, one 18F-FAZA PET scan will be conducted in patients with known squamous cell carcinoma of the Head ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Male or female greater than or equal to 16 years of age.
- If female of child-bearing potential and outside of the window of 10 days since the first day of the last menstrual period, a negative pregnancy test is required.
- Patients with known primary or suspected metastatic squamous cell carcinoma of the head and neck, non-small cell or small cell carcinoma of the lung, lymphoma, GBM (greater than or equal to 3 glioma), neuroendocrine tumours, or renal cell carcinoma with at least one lesion \>1 cm in diameter.
Exclusion
Key Trial Info
Start Date :
September 12 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 4 2019
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT00323076
Start Date
September 12 2006
End Date
February 4 2019
Last Update
August 26 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2